Characteristics of aplastic anemia patients given cyclophosphamide/antithymocyte globulin (CY/ATG) conditioning and HLA-matched related grafts. Data from Fred Hutchinson Cancer Research Center, Seattle VA Medical Center, Stanford University, and City of Hope.28
| Patients studied, number of patients (n) | 94 |
| Median age (range), yrs | 26 (2–59) |
| Gender (F/M), n | 38/56 |
| Possible causes, n | |
| Unknown | 76 |
| Hepatitis | 7 |
| Pregnancy | 4 |
| Drugs or chemicals | 5 |
| Dyskeratosis congenita | 1 |
| Fanconi anemia | 1 |
| Transfused before transplant, % | 94 |
| History of treatment, n | |
| Antithymocyte globulin | 21 |
| Cyclosporine | 22 |
| Steroids | 32 |
| Androgens | 11 |
| Any immunosuppression | 38 |
| Granulocyte colony-stimulating factor | 17 |
| Median duration of aplastic anemia (range), mo | 2.4 (0.2–146.6) |
| Patients studied, number of patients (n) | 94 |
| Median age (range), yrs | 26 (2–59) |
| Gender (F/M), n | 38/56 |
| Possible causes, n | |
| Unknown | 76 |
| Hepatitis | 7 |
| Pregnancy | 4 |
| Drugs or chemicals | 5 |
| Dyskeratosis congenita | 1 |
| Fanconi anemia | 1 |
| Transfused before transplant, % | 94 |
| History of treatment, n | |
| Antithymocyte globulin | 21 |
| Cyclosporine | 22 |
| Steroids | 32 |
| Androgens | 11 |
| Any immunosuppression | 38 |
| Granulocyte colony-stimulating factor | 17 |
| Median duration of aplastic anemia (range), mo | 2.4 (0.2–146.6) |